Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02110355
Title A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Amgen
Indications

melanoma

Therapies

KRT-232 + Trametinib

Dabrafenib + KRT-232 + Trametinib

Dabrafenib + Trametinib

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Research Site Los Angeles California 90095 United States Details
Research Site Aurora Colorado 80045 United States Details
Research Site Boston Massachusetts 02114 United States Details
Research Site Chapel Hill North Carolina 27599 United States Details
Research Site Nashville Tennessee 37232 United States Details
Research Site North Sydney New South Wales 2060 Australia Details
Research Site Melbourne Victoria 3000 Australia Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field